Key opinion leaders (KOLs) are important to pharma, as they lend a qualified and esteemed voice to your brand strategy. While industry regulations provide substantial hurdles for pharma communications, KOLs have better engagement with larger physician networks. Traditionally, the value of KOLs was in their ability to move a market. Although this fact hasn’t changed, […]

On May 24, 2019, the United States Food and Drug Administration (FDA) granted approval to the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib for use in combination with fulvestrant for treatment of women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer who carry PIK3CA mutations and have progressed on […]

Despite advances in cancer screening and detection, many cancers are not diagnosed until after they have metastasized. In patients with aggressive malignancies or severe comorbidities, survival can be limited. There has been relatively little information about treatment and outcomes in this population. To better understand treatment patterns in patients with poor prognosis, a study of […]

On May 13, 2019, the United States Food and Drug Administration (FDA) expanded the indication of the angiogenesis inhibitor ramucirumab to include use in patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of greater than or equal to 400 ng/mL and have previously been treated with sorafenib. This decision was based on results […]

Exciting new developments emerge from the oncology and hematology fields constantly. While many changes unfold over time, some announcements, new discoveries, and novel products are unveiled at annual conferences. Major oncology conferences include those of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). Important hematology conferences include the […]

Immunotherapy with PD-1 and PD-L1 inhibitors has been a welcome addition to cancer treatment across numerous tumor types. While these agents are highly effective in some patients, they can be associated with severe, long-lasting adverse events (AEs). To better capture the incidence of AEs associated with PD-(L)1 inhibitors, a recent meta-analysis published in JAMA Oncology […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and essentially get to the why. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices along with leading scientific experts […]

On April 18, 2019, the United States Food and Drug Administration (FDA) issued a draft guidance for industry on the development of bispecific antibodies. This guidance outlines general considerations and recommendations for any new bispecific antibody development program, and also provides specific information regarding quality testing, nonclinical pharmacology and toxicology studies, clinical pharmacokinetic and pharmacodynamic […]

The fields of oncology and hematology are fast-paced. New studies are published every day, offering fresh information and insights into diseases and treatments. This emerging research changes the landscape of medical information on which clinicians base their decisions. In addition, doctors’ experiences and collaborations within clinics and hospitals evolve over time. This progression impacts how […]